Aytu Biopharma (AYTU) Q3 2026 earnings summary

Executive summary

• EXXUA, a novel treatment for major depressive disorder (MDD), completed its first partial commercial launch quarter, generating $2.4 million in net revenue with over 1,300 prescriptions and more than 450 unique prescribers, reflecting strong early adoption and rapid prescription growth.

• The company shifted its commercial focus from ADHD and pediatric portfolios to EXXUA, resulting in expected revenue declines in legacy products but maintaining profitability and cash flow to support EXXUA's growth.

• Successfully launched EXXUA in Q2 FY2026, with the launch strategy emphasizing targeted prescribers, disciplined investment, and leveraging the RxConnect platform to reduce access barriers.

• Suspended clinical development programs and divested unprofitable operations, including the Consumer Health business, to focus on core CNS medicines.

• Entered international agreements to commercialize ADHD products in Israel, the Palestinian Authority, and Canada.

Financial highlights

• Q3 fiscal 2026 net revenue was $12.4 million, down 33% year-over-year from $18.5 million, reflecting the transition to EXXUA and reduced legacy portfolio sales.

• Gross profit was $7.6 million (61% margin), down from $12.8 million (69%) year-over-year, impacted by a $700,000 inventory write-down.

• Net loss was $5.6 million ($0.53 per share), compared to net income of $4 million ($0.65 per share) in the prior year, with adjusted EBITDA at -$2.8 million (vs. +$3.9 million prior year).

• Cash and cash equivalents were $26.7 million at quarter end, with total debt of $11.4 million.

• Stockholders' equity increased to $35.1 million from $14.2 million at prior quarter end, aided by warrant amendments.

Outlook and guidance

• Management expects mid to high 60% gross margins over time, disciplined operating expenses, and a near-term path to profitability as EXXUA revenue builds.

• Planned increases in sales and marketing spend ($1–2 million) and G&A ($200,000–300,000) in Q4 to support online campaigns and educational initiatives.

• Focus remains on accelerating commercial business growth, expanding prescriber base, improving access and reimbursement, and scaling scientific engagement.

• Management continues to evaluate strategic transactions and partnerships.